Back to today’s briefing

Story perspectives

Berlin Cures’ Long COVID Drug Trial Yields Disappointing Results

7/23/2025

39 6

Summary

Story summary

Berlin Cures, a German start-up, concluded its phase II clinical trial for the Long COVID drug BC 007 in November 2024, citing disappointing results. Although a few participants experienced symptom relief, experts criticized the study's design for failing to accurately assess these improvements, casting doubt on the drug's true effectiveness.

1 of 1

Story summary

Berlin Cures, a German start-up, concluded its phase II clinical trial for the Long COVID drug BC 007 in November 2024, citing disappointing results. Although a few participants experienced symptom relief, experts criticized the study's design for failing to accurately assess these improvements, casting doubt on the drug's true effectiveness.